Technology Bundle ID: TAB-2640

Real-time PCR Assays for Selective Detection and Differentiation of B. pertussis, B. parapertussis and B. homesii

Request More Info
Licensing Contact:
Primary Inventors: 
Kathleen Tatti (CDC)
Co-Inventors: 
Kansas Sparks (CDC), Maria-Lucia Tondella (CDC)
Therapeutic Area: 
Infectious Disease
Application: 
Diagnostics
Development Status: 
  • Early-stage
  • In vitro data available
Institute or Center: 
CDC

CDC researchers developed a real-time PCR assay targeting insertion sequence (IS481) and pertussis toxin subunit 1 (ptxS1) of Bordetella pertussis. This real-time nucleic acid assay offers rapid, sensitive, and quantitative results. The employed primers have been validated through extensive diagnostic testing of 41 Bordetella and 64 non-Bordetella clinical isolates. This technology can be used to diagnose and distinguish B. pertussis, B. parapertussis and B. homesii, the three most common Bordetella human upper respiratory pathogens. A standalone assay or multi-faceted kit may be used.

Applications:
  • Diagnostics for Bordetella pathogens
  • Investigation of acute upper respiratory illness and outbreaks
Advantages:
  • Validated for the three major pathogens responsible for Bordetella-related upper respiratory infections
  • Rapid, sensitive and quantitative
  • Easily adapted to kit form
  • Useful as an added, internal control for present Bordetella pertussis diagnostics

Patents

PCT Application PCT/US2010/032408
Filed on 2010-04-26
US Application 61/172,382
Filed on 2009-04-24
US Pat 9,096,908

Issued 2015-08-04

Publications

Tatti KM, et al.
PMID 18440175

Updated

Sep 17, 2013

Data Source: 
tts